216eP MegaMOST - A multicenter, open-label, molecularly selected bayesian phase II platform trial in advanced or metastatic solid tumors: Final analysis of the trametinib cohort. - Tredan, O.; Saada, E.B.; Dalban, C.; Cousin, S.; Le Cesne, A.; Italiano, A.; Bertucci, F.; Gomez-Roca, C.A.; Eberst, L.; Ray-Coquard, I.L.; Verlingue, L.; Cassier, P.; et al. (Annals of Oncology, 2025)